CAPS Capstone Therapeutics Corporation (QB)

EDISON EQUITY RESEARCH: CAPSTONE THERAPEUTICS - FOCUS ON ACUTE PANCREATITIS


Capstone is investigating a promising new indication for its Apo-E mimetics triglyceride lowering in acute pancreatitis, an orphan indication with high unmet medical need and requiring only small, rapid clinical trials. AEM-28 has demonstrated significant reductions in VLDL and triglycerides in its Phase I/IIa programme and development for follow-on AEM-28-02 is underway. However, new funding will be needed to progress clinical trials. 

Capstone Therapeutics’ lead candidate AEM-28 has completed a Phase I/II clinical trial for orphan disease homozygous familial hypercholesterolemia. Follow-on AEM-28-02 also has potential in broader CV indications. Capstone owns 60% of AEM-28 through a JV with LipimetiX Development..


To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports